Lotronex Withdrawal Reflects Danger Of First-To-Market Products, GSK Says

The withdrawal of Lotronex indicates the risk of launching the first product for a new indication in the current regulatory environment, GlaxoSmithKline Senior VP-New Product Development James Palmer maintained during a securities analysts meeting in London Feb. 22.